Advanced Enzyme Tech Intrinsic Value
Advanced Enzyme Tech (ADVENZYMES) median intrinsic value is ₹603.45 from 9 valuation models (range ₹98–₹794), vs current price ₹317.60 — +90.0% upside (Trading Below Calculated Value), margin of safety 47.4%. For current market price and key ratios, visit ADVENZYMES stock price BSE.
ADVENZYMES Valuation Methods Summary — DCF, Graham Number & P/E
Advanced Enzyme Tech intrinsic value across 9 models vs current price ₹317.60 — upside/downside and value range per method. Analyse Advanced Enzyme Tech ownership structure to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹337.92 | ₹270.34 - ₹405.50 | +6.4% | EPS: ₹15.36, Sector P/E: 22x |
| Book Value Method | asset | ₹794.00 | ₹714.60 - ₹873.40 | +150.0% | Book Value/Share: ₹741.82, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹635.20 | ₹571.68 - ₹698.72 | +100.0% | Revenue/Share: ₹383.64, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹635.20 | ₹571.68 - ₹698.72 | +100.0% | EBITDA: ₹284.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹603.45 | ₹482.76 - ₹724.14 | +90.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹98.30 | ₹88.47 - ₹108.13 | -69.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹237.31 | ₹213.58 - ₹261.04 | -25.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹635.20 | ₹571.68 - ₹698.72 | +100.0% | ROE: 11.0%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹506.33 | ₹455.70 - ₹556.96 | +59.4% | EPS: ₹15.36, BVPS: ₹741.82 |
ADVENZYMES Intrinsic Value vs Market Price — All Valuation Models
Advanced Enzyme Tech fair value range ₹98–₹794 vs current market price ₹317.60 across 9 valuation models. Read ADVENZYMES dividend history for the complete payout history and dividend yield track record.
ADVENZYMES Intrinsic Value Analysis — Undervalued or Overvalued?
Advanced Enzyme Tech median intrinsic value ₹603.45, current price ₹317.60 — Trading Below Calculated Value by 90.0%, margin of safety 47.4%.
What is the intrinsic value of ADVENZYMES?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Advanced Enzyme Tech (ADVENZYMES) is ₹603.45 (median value). With the current market price of ₹317.60, this represents a +90.0% variance from our estimated fair value.
The valuation range spans from ₹98.30 to ₹794.00, indicating ₹98.30 - ₹794.00.
Is ADVENZYMES undervalued or overvalued?
Based on our multi-method analysis, Advanced Enzyme Tech (ADVENZYMES) appears to be trading below calculated value by approximately 90.0%.
ADVENZYMES Financial Health — Key Ratios vs Industry Benchmarks
Advanced Enzyme Tech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 21.31 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.46x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ADVENZYMES Cash Flow Quality — Operating & Free Cash Flow
Advanced Enzyme Tech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹143 Cr | ₹98 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹141 Cr | ₹109 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹140 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹122 Cr | ₹122 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹163 Cr | ₹150 Cr | Positive Free Cash Flow | 8/10 |